Mechanistic Modeling of the Hepatic Disposition of Estradiol-17 β -Glucuronide in Sandwich-Cultured Human Hepatocytes

Katsuaki Ito,¹ Noora Sjöstedt,¹ and Kim L.R. Brouwer

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (K.I., N.S., K.L.R.B.); and DMPK Research Department, Teijin Pharma Limited, Hino, Tokyo, Japan (K.I.)

Received July 31, 2019; accepted November 12, 2019

ABSTRACT

Estradiol-17 β -glucuronide (E₂17G) is an estrogen metabolite that has cholestatic properties. In humans, circulating E₂17G is transported into hepatocytes by organic anion transporting polypeptides (OATPs) and is excreted into bile by multidrug-resistance associated protein 2 (MRP2). E₂17G is also a substrate of the basolateral efflux transporters MRP3 and MRP4, which translocate E₂17G from hepatocytes to blood. However, the contribution of basolateral efflux to hepatocyte disposition of E₂17G has not been evaluated previously. To address this question, E₂17G disposition was studied in sandwich-cultured human hepatocytes and mechanistic modeling was applied to calculate clearance values (mean $\pm$ S.D.) for uptake, intrinsic biliary excretion (CL_{int,bile}) and intrinsic basolateral efflux (CL_{int,BL}). The biliary excretion index of E₂17G was 45% $\pm$ 6%. The CL_{int,BL} of E₂17G [0.18 $\pm$ 0.03 (ml/min)/g liver] was 1.6-fold higher than CL_{int,bile} [0.11 $\pm$ 0.06 (ml/min)/g liver]. Simulations were performed to study the effects of increased CL_{int,BL} and a concomitant decrease in CL_{int,bile} on hepatic E₂17G exposure. Results demonstrated that increased CL_{int,BL} can effectively reduce hepatocellular and biliary exposure to this potent cholestatic agent.

Simulations also revealed that basolateral efflux can compensate for impaired biliary excretion and, vice versa, to avoid accumulation of E₂17G in hepatocytes. However, when both clearance processes are impaired by 90%, hepatocyte E₂17G exposure increases up to 10-fold. These data highlight the contribution of basolateral efflux transport, in addition to MRP2-mediated biliary excretion, to E₂17G disposition in human hepatocytes. This elimination route could be important, especially in cases where basolateral efflux is induced, such as cholestasis.

SIGNIFICANCE STATEMENT

The disposition of the cholestatic estrogen metabolite estradiol-17 β -glucuronide (E₂17G) was characterized in sandwich-cultured human hepatocytes. The intrinsic basolateral efflux clearance was estimated to be 1.6-fold higher than the intrinsic biliary excretion clearance, emphasizing the contribution of basolateral elimination in addition to biliary excretion. Simulations highlight how hepatocytes can effectively cope with increased E₂17G through the regulation of both basolateral and biliary transporters.

Introduction

Estradiol-17 β -glucuronide (E₂17G) is a metabolite of estradiol, an estrogen steroid hormone. E₂17G is formed by uridine 5'-diphosphoglucuronosyltransferase-mediated glucuronidation of estradiol, primarily

This work was supported by the National Institute of General Medical Sciences of the National Institutes of Health [Award Number R35 GM122576] (K.L.R.B.) and by Teijin Pharma Limited. N.S. was supported by the Sigrid Jusélius Foundation.

¹K.I. and N.S. contributed equally to this work.

This work was presented, in part, at the AAPS 2018 PharmSci 360 (Washington, DC, November 4–7, 2018).

K.L.R.B. is a co-inventor of the sandwich-cultured hepatocyte technology for quantification of biliary excretion (B-CLEAR[®]) and related technologies, which have been licensed exclusively to Qualyst Transporter Solutions, recently acquired by BioIVT. B-CLEAR[®] is covered by U.S. patent 6,780,580 and other U.S. and international patents both issued and pending.

<https://doi.org/10.1124/dmd.119.088898>.

in the liver (Musey et al., 1997; Itäaho et al., 2008). Hepatic concentrations of E₂17G are regulated by multiple transport proteins expressed in the liver. E₂17G is a well-known substrate of multidrug-resistance associated protein 2 (MRP2, ABCC2), which mediates E₂17G excretion into bile (Morikawa et al., 2000). On the basolateral (sinusoidal) membrane, organic anion transporting polypeptides 1B1 and 1B3 (OATP1B1, SLCO1B1 and OATP1B3, SLCO1B1) mediate the uptake of E₂17G into hepatocytes from the blood (Karlgrén et al., 2012). In fact, E₂17G is commonly used as a probe substrate in OATP1B1/1B3 and MRP2 inhibition studies in vitro (Pedersen et al., 2008; Karlgrén et al., 2012; Brouwer et al., 2013; Morgan et al., 2013). In addition, E₂17G is transported by MRP3 (ABCC3) and MRP4 (ABCC4), which pump substrates from hepatocytes into sinusoidal blood on the basolateral membrane (Zeng et al., 2000; Chen et al., 2001). However, the contribution of basolateral efflux to the hepatic disposition of E₂17G has not been elucidated.

E₂17G transport is of interest because it is a potent cholestatic agent and it is postulated to be involved in the pathogenesis of intrahepatic

ABBREVIATIONS: BEI, biliary excretion index; BSEP, bile salt export pump; CL_{int,bile}, intrinsic biliary excretion clearance; CL_{int,BL}, intrinsic basolateral efflux clearance; CL_{uptake}, uptake clearance; E₂17G, estradiol-17 β -glucuronide; HBSS, Hanks' balanced salt solution; ICP, intrahepatic cholestasis of pregnancy; K_{flux}, rate constant for flux from bile into the medium; MRP, multidrug resistance-associated protein; OATP, organic anion transporting polypeptide; SCHH, sandwich-cultured human hepatocytes; TCA, taurocholate.

cholestasis of pregnancy (ICP). ICP is a condition that is characterized by fairly harmless pruritus and elevated serum bile acid concentrations in the mother, but can increase the risk for preterm labor or even intrauterine death (Geenes and Williamson, 2009). Maternal symptoms typically present in the third trimester of pregnancy, coinciding with the highest estrogen levels during pregnancy. Therefore, it is thought that elevated hepatic E₂17G concentrations may play a role in triggering ICP. Understanding the mechanisms underlying the hepatic disposition of E₂17G is important from the viewpoint of preventing and managing ICP.

Most of the studies regarding the cholestatic effects of E₂17G have been performed in rats. E₂17G administration (2 μmol infused over 18 minutes) decreased bile flow by 51% in perfused rat livers (Huang et al., 2000). Additionally, E₂17G decreased the elimination of the hepatobiliary imaging agent indocyanine green in female rhesus monkeys (Slikker et al., 1983). MRP2 seems to play a key role in E₂17G-induced cholestasis, because even doses 12-fold higher than the dose required for cholestatic effects in wild-type rats did not decrease bile flow in Mrp2-deficient TR⁻ rats (Huang et al., 2000). Studies in Mrp2-deficient rats have shown that Mrp2 mediates the secretion of glutathione into bile and that this is important for bile acid-independent bile flow (Takikawa et al., 1991; Elferink and Groen, 2002). Overall, E₂17G appears to exert its cholestatic effects through several mechanisms. Administration of E₂17G to rats increased the internalization of Mrp2 and the bile salt export pump (Bsep) from the cell membrane by clathrin-mediated endocytosis (Mottino et al., 2002; Miszczuk et al., 2018). In addition, E₂17G increased the accumulation of bile acids through trans-inhibition of BSEP (Stieger et al., 2000; Vallejo et al., 2006). An increase in intrahepatic bile acid concentrations could induce organic solute transporter α/β expression (Boyer et al., 2006) and enhance bile acid efflux into the blood, which might explain the observed increase in serum bile acids in ICP (Walker et al., 2002).

Although the current literature suggests a possible role for MRP2 in E₂17G-induced ICP, as discussed above, several mechanisms appear to be involved in the development of ICP, and MRP2 is not the only process regulating hepatic E₂17G exposure. The exposure also is affected by hepatic basolateral uptake and efflux transporters. Therefore, in this study, the contribution of basolateral efflux in the hepatic disposition of E₂17G was quantitatively evaluated by uptake and efflux studies using sandwich-cultured human hepatocytes (SCHH) and mechanistic modeling. The clearance estimates derived from the model were used to simulate conditions resulting in inhibition or induction of the different pathways affected by cholestasis or drug-drug interactions based on previously published literature. The results of this study reinforce the notion that basolateral efflux can act as an important excretion route for E₂17G, especially in cholestatic conditions where basolateral transporters (e.g., MRP3, MRP4) are upregulated.

Materials and Methods

Materials. Transporter certified cryopreserved human hepatocytes (three female donors, Table 1) were obtained from ThermoFisher Scientific (Waltham, MA) and In Vitro ADMET Laboratories (Columbia, MD). QualGro™ seeding medium and QualGro™ hepatocyte culture medium were obtained from BioIVT (Durham, NC). Tritium-labeled estradiol-17β-glucuronide ([³H]-E₂17G) (52.9 Ci/mmol, radiochemical purity >97%) and taurocholate ([³H]-TCA) (9.7 Ci/mmol, radiochemical purity >97%) were purchased from PerkinElmer (Boston, MA). Nonlabeled E₂17G and TCA were purchased from Sigma-Aldrich (St. Louis, MO). Standard Hank's balanced salt solution (HBSS) and HBSS without calcium and magnesium were purchased from ThermoFisher Scientific. Collagen (type I)-coated BioCoat™ 24-well cell culture plates and Matrigel® were obtained from BD Biosciences (San Jose, CA).

Sandwich-Cultured Human Hepatocytes. On day 0, human hepatocytes from the three donors were seeded on BioCoat™ 24-well plates at a density of

TABLE 1

Donor information for the three hepatocyte lots used in the studies

All donors were women.

	Lot 1	Lot 2	Lot 3
Race	Caucasian	Caucasian	Caucasian/Hispanic
Age (yr)	37	55	44
BMI (kg/m ²)	22	24	29
Cause of death	Head trauma	Stroke	Anoxia, cerebrovascular accident

0.45×10^6 hepatocytes per well using QualGro™ seeding medium and overlaid with Matrigel® diluted in QualGro™ hepatocyte culture medium (0.25 mg/ml) on day 1. SCHH were maintained in QualGro™ hepatocyte culture medium, which was changed daily until experiments were performed on day 5.

Disposition of E₂17G in SCHH. The uptake and efflux studies were conducted by applying B-CLEAR® technology (BioIVT) according to the schemes shown in Fig. 1 (Liu et al., 1999). Briefly, SCHH were washed twice and preincubated for 10 minutes at 37°C with either standard HBSS (containing calcium and magnesium) or Ca²⁺-free HBSS (HBSS without calcium and magnesium, supplemented with 1 mM EGTA). After preincubation, the uptake phase was initiated by incubating SCHH with 0.3 μM [³H]-E₂17G (2 μCi/ml) in standard HBSS at 37°C. E₂17G accumulation in cells and biliary networks (cells + bile; measured in SCHH preincubated with standard HBSS) and E₂17G accumulation in cells (measured in SCHH preincubated with Ca²⁺-free HBSS) was determined during the uptake phase by terminal sampling at designated time points. After the 10-minute uptake phase, buffers containing E₂17G were removed from the wells and cells were washed three times with 37°C standard or Ca²⁺-free HBSS buffer followed by initiation of the efflux phase. During the efflux phase, E₂17G efflux into the buffer and the amount remaining in cells and biliary networks (standard HBSS preincubation) and cells (Ca²⁺-free HBSS preincubation) were determined by terminal sampling at designated time points. In addition, B-CLEAR® studies were performed as above with taurocholate (TCA) for comparison with the E₂17G results. In these studies, SCHH were incubated with 1 μM TCA (0.8 μCi/ml) for 10 minutes in standard HBSS after a 10-minute preincubation in standard HBSS or Ca²⁺-free HBSS. Accumulation of TCA in the cells and cells + bile was determined by terminal sampling.

The radioactivity in samples from cells, cells + bile, and buffer was quantified by liquid scintillation counting using a Tri-Carb 3100TR counter (Perkin Elmer). Prior to analysis, cells were lysed with lysis solution containing 1× phosphate-buffered saline with 0.5% Triton X-100. Total protein concentration of the cell lysates was determined using the Pierce™ BCA Protein Assay Kit (ThermoFisher Scientific). The amount of E₂17G and TCA measured in the cell and the buffer samples was normalized to the protein amount in the wells. The biliary excretion index (BEI) was calculated from data at the end of the 10-minute uptake phase using eq. 1:

$$BEI(\%) = \frac{X_{\text{cells + bile}} - X_{\text{cells}}}{X_{\text{cells + bile}}} \times 100 \quad (1)$$

where $X_{\text{cells + bile}}$ is the amount of test compound (E₂17G or TCA) accumulated in the cells and bile networks in standard HBSS, and X_{cells} is the amount of test compound accumulated in the cells that were preincubated in Ca²⁺-free HBSS.

Mechanistic Modeling of E₂17G in SCHH. Mechanistic modeling was applied to the uptake and efflux data using Phoenix WinNonlin, v7.0 (Certara USA, Princeton, NJ) using a previously reported approach (Pfeifer et al., 2013). Briefly, the mechanistic model depicted in Fig. 1 was fit simultaneously to the E₂17G uptake and efflux in standard and Ca²⁺-free HBSS versus time data. The basolateral uptake clearance (CL_{uptake}), intrinsic basolateral efflux clearance ($CL_{\text{int,BL}}$), intrinsic biliary excretion clearance ($CL_{\text{int,bile}}$), and the first-order rate constant for flux from the bile network into the buffer (K_{flux}) were determined. Assuming non-saturable clearances for all the pathways, the model equations are as follows:

Mass of E₂17G in standard HBSS (X_{buffer}^+):

$$\frac{dX_{\text{buffer}}^+}{dt} = C_{\text{cells}}^+ \times CL_{\text{int,BL}} + X_{\text{bile}} \times K_{\text{flux}} - C_{\text{buffer}}^+ \times CL_{\text{uptake}} - X_{\text{buffer}}^+ \times K_{\text{wash}} \quad (2)$$

Fig. 1. Scheme depicting the uptake and efflux studies performed in SCHH with E₂17G. (A) Test compound (E₂17G) is taken up into the cells via uptake transporters (CL_{uptake}) and excreted from the cell to the medium by transporters on the basolateral membrane (CL_{int,BL}) or into the bile by canalicular transporters (CL_{int,bile}). In the presence of Ca²⁺, E₂17G accumulates in the bile canaliculi but can flux into the medium (K_{flux}) with contractions of the canaliculi. When incubated in Ca²⁺-free buffer, the tight junctions of the bile canaliculi are disrupted and all excreted compound returns to the buffer. (B) Summary of the SCHH uptake and efflux study protocol performed in the presence and absence of Ca²⁺ to determine biliary excretion.

Mass of E₂17G in Ca²⁺-free HBSS (X_{buffer}⁻):

$$\frac{dX_{\text{buffer}}^-}{dt} = C_{\text{cells}}^- \times \text{CL}_{\text{int,BL}} - C_{\text{buffer}}^- \times \text{CL}_{\text{uptake}} - X_{\text{buffer}}^- \times K_{\text{wash}} + C_{\text{cells}}^- \times \text{CL}_{\text{int,bile}} \quad (3)$$

Mass of E₂17G in cells (X_{cells}):

$$\frac{dX_{\text{cells}}}{dt} = C_{\text{buffer}} \times \text{CL}_{\text{uptake}} - C_{\text{cells}} \times (\text{CL}_{\text{int,BL}} + \text{CL}_{\text{int,bile}}) \quad (4)$$

Mass of E₂17G in bile (X_{bile}):

$$\frac{dX_{\text{bile}}}{dt} = C_{\text{cells}} \times \text{CL}_{\text{int,bile}} - X_{\text{bile}} \times K_{\text{flux}} \quad (5)$$

Mass of E₂17G in cells + bile (X_{cells+bile}):

$$\frac{dX_{\text{cells+bile}}}{dt} = \frac{X_{\text{bile}}}{dt} + \frac{X_{\text{cells}}}{dt} \quad (6)$$

The first-order rate constant K_{wash} was fixed at 10^4 minute^{-1} between 10 and 11 minutes in the simulations. This parameter was included to remove all E₂17G from the buffer and mimic the wash step between the uptake and efflux phases (Pfeifer et al., 2013; Yang et al., 2015). The initial mass of E₂17G in both buffers was set equal to the dose, and the initial mass in the other compartments was set equal to zero. The in vitro observations used for data fitting were E₂17G X_{cells+bile} and X_{buffer}⁺ in standard HBSS, and X_{cells} and X_{buffer}⁻ in Ca²⁺-free conditions. An additive error model was used for the mass of E₂17G in standard HBSS and in cells incubated in Ca²⁺-free buffer, and a Poisson error model (a power model with a coefficient of 0.5) was used for the other observations. The initial estimate for CL_{uptake} was calculated using the first three time points in the uptake phase as $(dX_{\text{cells+bile}}/dt)/C_{\text{buffer}}$. The total efflux clearance (CL_{int,BL} + CL_{int,bile}) was estimated from efflux phase data under Ca²⁺-free conditions, where $(\text{CL}_{\text{int,bile}} + \text{CL}_{\text{int,BL}}) = X_{\text{buffer},21 \text{ min}}^{\text{efflux}}/\text{area under the curve (AUC)}_{\text{cells},11-21 \text{ min}}$. Initial estimates were derived by dividing CL_{int,bile} + CL_{int,BL} by 2. The ordinary differential equations were solved using the matrix exponent ordinary differential equations solver in Phoenix WinNonlin. The goodness of fit was evaluated based on visual observation of predicted and observed E₂17G mass and the CV% of the derived parameter estimates. The model derived clearance values were scaled to the liver and expressed as milliliter per minute per gram liver, assuming a protein content of 90 mg protein/g liver (Sohlenius-Sternbeck, 2006). The fraction excreted by the two elimination pathways (f_{e,bile} and f_{e,efflux,BL}) were calculated as the ratio of the specific clearance pathway divided by the sum of both clearance values (Zamek-Gliszczyński et al., 2009).

Effect of Transporter Induction and Inhibition. The effect of transporter induction on E₂17G disposition was evaluated by simulating disposition in SCHH using the average clearance estimates derived from the mechanistic modeling.

Simulations were performed using Stella version 9 (Isee Systems Inc., Lebanon, NH) and eqs. 2–6. CL_{int,bile} was decreased and CL_{int,BL} was increased by 2- and 4-fold in the simulations. These values were chosen to represent plausible changes in protein levels based on available literature (Thakkar et al., 2017). The BEI was calculated for each of the simulations using eq. 1 and simulated E₂17G amounts after 10-minute uptake. Simulations (up to 60 minutes) were performed to evaluate the changes in E₂17G in the cells and bile compartments at steady-state due to transporter induction. In addition, the effect of inhibition of CL_{int,bile} and/or CL_{int,BL} on E₂17G accumulation at steady state was calculated using eq. 7 and varying the clearance values:

$$K_p = \frac{\text{CL}_{\text{uptake}}}{\text{CL}_{\text{int,BL}} + \text{CL}_{\text{int,bile}}} \quad (7)$$

where K_p is the hepatocyte to buffer concentration ratio. All data from the simulations and K_p calculations were normalized to control values (no inhibition or induction).

Results

All three hepatocyte lots showed time-dependent accumulation of E₂17G into cells during the uptake phase and excretion into the buffer during the efflux phase (Fig. 2). The biliary excretion index (BEI) of E₂17G after 10-minute uptake was 40%–52% in the three lots (Fig. 3). The functionality of the hepatocyte lots was verified with TCA; the BEI of TCA in the same hepatocyte lots was 41%–62%. All of the observed time course data for E₂17G uptake and efflux were described adequately by the model, and the CVs of the derived parameters were ≤68%. The largest variability in parameter estimates between lots was seen for CL_{int,bile} (55% CV between lots). The average value of CL_{int,BL} [$0.18 \pm 0.03 \text{ (ml/min)/g liver}$] was 1.6-fold higher than CL_{int,bile} [$0.11 \pm 0.06 \text{ (ml/min)/g liver}$] (Table 2). The average fraction of E₂17G excreted via basolateral efflux (f_{e,efflux,BL}) was 62%, and 38% was excreted via biliary excretion (f_{e,bile}).

Sensitivity analysis revealed that hepatic E₂17G exposure is sensitive to CL_{int,BL}; a 64% decrease in hepatic E₂17G exposure was observed when basolateral efflux was increased by fourfold (Fig. 4A). A decrease in CL_{int,bile} caused an increase in hepatic E₂17G exposure, especially when CL_{int,BL} was unchanged. However, when CL_{int,BL} was simultaneously increased fourfold, even a fourfold reduction in CL_{int,bile} had minimal effects on E₂17G in hepatocytes. E₂17G in bile was decreased to a similar extent by a twofold increase in CL_{int,BL} and a twofold decrease in CL_{int,bile} (Fig. 4B). The same was true for a fourfold increase in CL_{int,BL} and a fourfold decrease in CL_{int,bile} (Fig. 4B).

Fig. 2. E₂17G mass (pmol/mg protein) vs. time data in SCHH during the uptake and efflux phase. SCHH were incubated with 0.3 μ M [³H]-E₂17G (2 μ Ci/ml) according to the scheme presented in Fig. 1B. The simulated mass-time profiles were generated using the relevant equations based on the model scheme depicted in Fig. 1A; the final parameter estimates are reported in Table 2. Data are presented as the mean $\pm$ S.D. ($n = 3$ wells, except $n = 2$ for cell lysate sample in Lot 1 at 0.5 minute with Ca²⁺-free HBSS).

The maximal simulated decrease in biliary E₂17G was 90%, which was achieved with a fourfold increase in CL_{int,BL} and a fourfold decrease in CL_{int,bile} (Fig 4B). The BEI was only marginally affected by changes in CL_{int,BL}; the BEI of E₂17G was decreased more than 30% when CL_{int,bile} was reduced twofold and more than 60% when CL_{int,bile} was reduced fourfold (Fig. 4C).

The results of simulations to evaluate the impact of inhibition of biliary excretion and/or basolateral efflux of E₂17G on hepatic exposure are plotted in Fig. 5. As shown, only modest changes (under twofold) in E₂17G hepatic exposure occurred when CL_{int,bile} was inhibited by 90% because basolateral efflux compensated for impaired biliary excretion. Likewise, E₂17G hepatic exposure increased no more than 2.3-fold when CL_{int,BL} was inhibited by 90% due to compensation by biliary excretion. However, up to a 10-fold increase in E₂17G hepatic exposure was observed when both CL_{int,BL} and CL_{int,bile} were inhibited simultaneously up to 90% of control values.

Discussion

Understanding hepatic E₂17G disposition is important because E₂17G plays a role in ICP and susceptibility could change if transporter expression is altered by disease or drug interactions. Therefore, this study characterized E₂17G disposition in SCHH using the uptake and efflux protocol and mechanistic modeling previously established (Pfeifer et al., 2013) to estimate basolateral uptake and efflux clearance values and biliary excretion clearance. These values were used to study the relative contribution of the different pathways and simulate effects of cholestasis-mediated transporter alterations or drug-drug interactions on hepatic E₂17G disposition.

The biliary excretion of E₂17G by Mrp2 is well documented (Huang et al., 2000; Morikawa et al., 2000). The influence of biliary excretion on E₂17G disposition in SCHH is indicated by the BEI, which ranged from

40% to 52% in the three hepatocyte lots. This BEI range for E₂17G agrees with previously published values of 32%–43% (Bi et al., 2006; Lee et al., 2010). The mean E₂17G CL_{int,bile} estimate determined here [0.11 (ml/min)/g liver] was similar to TCA CL_{int,bile} [0.14 (ml/min)/g liver] determined previously (Yang et al., 2015). Whereas TCA is predominantly excreted into bile in SCHH (Yang et al., 2015), this is not the case for E₂17G. The CL_{int,BL} of TCA is 3.3-fold lower than CL_{int,bile} (Yang et al., 2015). In contrast, based on our results, the CL_{int,BL} of E₂17G is 1.6-fold higher than CL_{int,bile} (Table 2). Thus, basolateral efflux is an important route of E₂17G elimination in SCHH. It should be noted that there is inter-donor variability in the ratio of CL_{int,BL} to CL_{int,bile}; the ratio is 0.9, 2.0, and 2.9 in hepatocyte Lots 1, 2, and 3, respectively (Table 2). This variability is expected based on large individual differences in protein levels of hepatic efflux transporters. For example, MRP2 and MRP3 protein expression showed 6.6- and 3.7-fold individual differences, respectively, in human liver tissue from more than 50 donors (Deo et al., 2012; Wang et al., 2015).

At the basolateral membranes of hepatocytes, MRP3 and MRP4 transport substrates from the cells to the sinusoidal blood (Chandra and Brouwer, 2004). Although our data cannot identify the transporters responsible for the basolateral efflux of E₂17G, it is likely to be mediated by MRP3 and/or MRP4, because E₂17G is a well-established substrate for these efflux transporters (Zeng et al., 2000; Chen et al., 2001). MRP3 and MRP4 have comparable K_m values for E₂17G (Zeng et al., 2000; Chen et al., 2001; Zamek-Gliszczynski et al., 2006). However, in human liver tissue, the absolute protein level of MRP3 is at least 40-fold higher than MRP4 (Vildhede et al., 2015). Thus, MRP3 is assumed to be the primary transporter mediating the hepatic basolateral efflux of E₂17G in healthy subjects. It should be noted that E₂17G is not a substrate of organic solute transporter α/β , which also is expressed on the basolateral membranes of hepatocytes (Malinen et al., 2018).

Fig. 3. Biliary excretion of E₂17G and TCA in SCHH. Accumulation (mean ± S.D.; *n* = 3) of substrate in SCHH after incubation with 0.3 μM [³H]-E₂17G (0.7 μCi/ml) or 1 μM [³H]-TCA (0.8 μCi/ml) for 10 minutes in standard HBSS after a 10-minute preincubation in standard HBSS (black bars; cells + bile) or Ca²⁺-free HBSS (white bars; cells). The BEI was calculated according to eq. 1.

The contribution of basolateral efflux to E₂17G elimination from hepatocytes could be amplified in situations where basolateral efflux transporter levels are increased. Basolateral transporters can be induced in several liver diseases, including cholestasis (Thakkar et al., 2017). For example, MRP3 protein levels increased 4.6-fold in patients with obstructive cholestasis caused by gall stones (Chai et al., 2012) and increased 2.1- to 2.6-fold in patients with stage III/IV primary biliary cirrhosis (Zollner et al., 2003). A similar increase compared with control subjects was reported for MRP4 in obstructive cholestasis (3.1-fold) and primary biliary cirrhosis (3.2- to 3.5-fold) (Zollner et al., 2007; Chai et al., 2011). MRP3 and MRP4 protein levels also are increased in nonalcoholic steatohepatitis (Hardwick et al., 2011). In addition, MRP3/ MRP3 is upregulated in MRP2-deficient TR⁻ rats and in patients with Dubin-Johnson syndrome (König et al., 1999; Johnson et al., 2006). In contrast, MRP2 levels do not appear to be changed in cholestasis in humans, but some studies point to a mislocalization of MRP2 in cholestatic disease (Zollner et al., 2001, 2003; Kojima et al., 2003; Chai et al., 2012).

A sensitivity analysis was performed to evaluate the effects of changes in efflux protein levels on hepatic E₂17G disposition. The analysis

revealed that hepatic E₂17G was sensitive to CL_{int,BL}; a fourfold increase in CL_{int,BL} decreased hepatic E₂17G by 64% (Fig. 4A). Biliary E₂17G also was examined because E₂17G in bile may play a role in the development of cholestasis through trans-inhibition of BSEP (Stieger et al., 2000). Biliary E₂17G was influenced by both basolateral and biliary transporters (Fig. 4B). Sensitivity analysis of CL_{int,bile} revealed that a decrease in CL_{int, bile} (e.g., MRP2 downregulation) effectively decreased the amount of E₂17G in bile (Fig. 4B). However, the effects on E₂17G accumulation in hepatocytes were smaller (Fig. 4A). Importantly, decreased CL_{int,bile} caused only a minimal increase in cellular E₂17G amounts when CL_{int,BL} was induced fourfold (Fig. 4A). These results suggest that induction of basolateral efflux transporters (e.g., MRP3 and MRP4) in cholestasis could lower the amount of E₂17G in hepatocytes, even when biliary clearance is impaired, and may help relieve cholestasis. Pregnant women with defects in these compensatory mechanisms could be predisposed to developing ICP.

The inhibition of MRP3 and MRP4 is a risk factor for drug-induced cholestasis (Morgan et al., 2013; Köck et al., 2014; Chan and Benet, 2018). In addition, MRP2 inhibition alongside possible mislocalization in cholestasis can disturb hepatocellular homeostasis of MRP2 substrates. As expected, our simulations revealed that inhibition of either CL_{int,BL} alone (i.e., MRP3 and MRP4 transport) or inhibition of CL_{int,bile} alone (i.e., MRP2 transport) has a minimal effect on hepatic E₂17G exposure (Fig. 5). This is consistent with the concept of fractional excretion (Zamek-Gliszczyński et al., 2009). Based on the calculated clearance estimates in SCHH, 62% of E₂17G is excreted via the basolateral pathway. Therefore, even a complete knockout of this predominant excretion pathway would only increase E₂17G in hepatocytes by a maximum of 2.6-fold, assuming that no changes in the compensatory biliary pathway occurred. However, simulations indicated that hepatic E₂17G was markedly increased with simultaneous inhibition of both pathways (Fig. 5). The simultaneous inhibition of several MRP transporters is a likely event due to overlap in the inhibitor specificity of MRPs (Morgan et al., 2013), and this may predispose patients to E₂17G-mediated cholestasis. For example, medications that have been associated with drug-induced liver injury and cholestasis (e.g., repaglinide, cyclosporine A, everolimus) exhibit overlapping inhibition of MRP2, MRP3, and MRP4 (Morgan et al., 2013).

The hepatic clearance estimates of E₂17G were determined assuming linear processes. No saturation of these pathways is expected with the 0.3 μM E₂17G dose used in this study. The apparent *K_m* for the uptake clearance of E₂17G in plated human hepatocytes is reported to be 7.7 μM (Liao et al., 2019), and the *K_m* values of E₂17G for MRP3 and MRP4 are in the range of 20–40 μM determined in vesicle studies (Zeng et al., 2000; Chen et al., 2001; Zamek-Gliszczyński et al., 2006). E₂17G shows cooperative binding and sigmoidal kinetics of MRP2-mediated transport in membrane vesicles with *K_m*/*K_{0.5}* values of >100 μM (Herédi-Szabó et al., 2009). The highest hepatocellular concentrations of E₂17G reached in this study were <1.5 μM. Therefore, we believe that the assumption of linearity is reasonable. Another simplification of the model was that passive permeability was not modeled as a separate

TABLE 2
Final parameter estimates from the model fitting

Hepatocyte lot	CL _{uptake}	CL _{int,BL}	CL _{int,bile}	K _{flux}
		(ml/min)/g liver (CV%)		min ⁻¹ (CV%)
Lot 1	0.69 (15%)	0.16 (68%)	0.18 (47%)	0.31 (41%)
Lot 2	1.2 (9%)	0.17 (19%)	0.083 (35%)	0.21 (22%)
Lot 3	0.98 (9%)	0.21 (14%)	0.073 (28%)	0.17 (22%)
Mean ± S.D.	0.96 ± 0.26	0.18 ± 0.03	0.11 ± 0.06	0.23 ± 0.07

Fig. 4. Effects of alterations in CL_{int,BL} and CL_{int,bile} on E₂17G disposition in SCHH. The impact of designated fold changes in clearance estimates on mean steady-state levels of E₂17G in cells (A) and bile (B), and on the BEI (C) at 10 minutes are plotted. All values were normalized to control simulations run using the average clearance estimates of E₂17G from the mechanistic modeling.

parameter. However, passive permeability has been shown previously to play a minor role in E₂17G uptake in hepatocytes, with active processes contributing to $89.3\% \pm 8.1\%$ of total uptake (Liao et al., 2019). The biliary excretion of E₂17G was decreased by more than 75% in the presence of the MRP2 inhibitor sulindac or its metabolite (Lee et al., 2010), suggesting that passive permeability is also minor in E₂17G efflux from hepatocytes.

SCHH continue to be a standard method for assessing hepatic disposition in vitro, particularly regarding transporter-mediated efflux (Brouwer et al., 2013). As bile networks re-form over days in culture, the levels of efflux transporters increase and exhibit appropriate functionality (Swift et al., 2010). An important consideration with this study is that levels of individual transporters in SCHH may differ from those in

Fig. 5. Effects of 0%–90% efflux inhibition on hepatic E₂17G exposure. The hepatocyte to buffer concentration ratio (K_p , eq. 7) was calculated using average clearance values (control) and decreasing either CL_{int,BL} and/or CL_{int,bile}. Exposure is shown as fold change from control (no inhibition). When CL_{int,bile} is inhibited by 90%, hepatic E₂17G exposure is 1.5-fold (point A). When CL_{int,BL} is inhibited by 90%, hepatic E₂17G exposure is 2.3-fold (point B). However, when both CL_{int,bile} and CL_{int,BL} are inhibited by 90%, the hepatic E₂17G exposure increases 10-fold (point C).

liver tissue, which could limit the ability to accurately translate data from in vitro to in vivo. Recently, the absolute protein abundance of MRP2 and MRP3, the primary transporters involved in hepatic E₂17G efflux, was reported to be approximately fourfold higher, on average, in SCHH than in liver tissue from corresponding donors (Kumar et al., 2019). However, the ratio of absolute levels of MRP2 to MRP3 was similar in SCHH and liver tissue (Kumar et al., 2019). Although protein abundance was not determined in the current study, the available literature suggests that the relative contribution of the efflux pathways of interest are similar in SCHH and in liver tissue.

In summary, this study revealed that basolateral efflux in addition to biliary excretion is a significant route of E₂17G elimination in SCHH. The importance of this elimination pathway is further emphasized when basolateral efflux transporter levels (e.g., MRP3 and MRP4) are increased, which may occur in conditions such as cholestasis. The simulations presented here highlight how hepatocytes can effectively cope with increased E₂17G through the regulation of both basolateral and biliary transporters.

Acknowledgments

The authors acknowledge Certara for providing Phoenix software to the UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, as part of the Pharsight Academic Center of Excellence Program.

Authorship Contributions

Participated in research design: Ito, Brouwer.

Conducted experiments: Ito, Sjöstedt.

Performed data analysis: Ito, Sjöstedt, Brouwer.

Wrote or contributed to the writing of the manuscript: Sjöstedt, Ito, Brouwer.

References

- Bi YA, Kazolias D, and Duignan DB (2006) Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. *Drug Metab Dispos* **34**:1658–1665.
- Boyer JL, Trauner M, Mennone A, Soroka CJ, Cai SY, Moustafa T, Zollner G, Lee JY, and Ballatori N (2006) Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. *Am J Physiol Gastrointest Liver Physiol* **290**:G1124–G1130.

- Brouwer KLR, Keppler D, Hoffmaster KA, Bow DA, Cheng Y, Lai Y, Palm JE, Stieger B, and Evers R; International Transporter Consortium (2013) In vitro methods to support transporter evaluation in drug discovery and development. *Clin Pharmacol Ther* **94**:95–112.
- Chai J, He Y, Cai SY, Jiang Z, Wang H, Li Q, Chen L, Peng Z, He X, Wu X, et al. (2012) Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway. *Hepatology* **55**:1485–1494.
- Chai J, Luo D, Wu X, Wang H, He Y, Li Q, Zhang Y, Chen L, Peng ZH, Xiao T, et al. (2011) Changes of organic anion transporter MRP4 and related nuclear receptors in human obstructive cholestasis. *J Gastrointest Surg* **15**:996–1004.
- Chan R and Benet LZ (2018) Measures of BSEP inhibition in vitro are not useful predictors of DILI. *Toxicol Sci* **162**:499–508.
- Chandra P and Brouwer KLR (2004) The complexities of hepatic drug transport: current knowledge and emerging concepts. *Pharm Res* **21**:719–735.
- Chen ZS, Lee K, and Kruh GD (2001) Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. *J Biol Chem* **276**:33747–33754.
- Deo A K, Prasad B, Balogh L, Lai Y, and Unadkat J K (2012) Interindividual Variability in Hepatic Expression of the Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2): Quantification by Liquid Chromatography/Tandem Mass Spectrometry. *Drug Metab Dispos* **40**:852–855.
- Elferink RO and Groen AK (2002) Genetic defects in hepatobiliary transport. *Biochim Biophys Acta* **1586**:129–145.
- Geenes V and Williamson C (2009) Intrahepatic cholestasis of pregnancy. *World J Gastroenterol* **15**:2049–2066.
- Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, and Cherrington NJ (2011) Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. *Drug Metab Dispos* **39**:2395–2402.
- Herédi-Szabó K, Glavinas H, Kis E, Méhn D, Báthori G, Veres Z, Kóbori L, von Richter O, Jemnitz K, and Krajcsi P (2009) Multidrug resistance protein 2-mediated estradiol-17beta-D-glucuronide transport potentiation: in vitro-in vivo correlation and species specificity. *Drug Metab Dispos* **37**:794–801.
- Huang L, Smit JW, Meijer DK, and Vore M (2000) MRP2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats. *Hepatology* **32**:66–72.
- Itäaho K, Mackenzie P I, Ikushiro S, Miners J O, and Finel M (2008) The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases. *Drug Metab Dispos* **36**:2307–2315.
- Johnson BM, Zhang P, Schuetz JD, and Brouwer KLR (2006) Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. *Drug Metab Dispos* **34**:556–562.
- Karlgrén M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, and Artursson P (2012) Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. *J Med Chem* **55**:4740–4763.
- Köck K, Ferslew BC, Netterberg I, Yang K, Urban TJ, Swaan PW, Stewart PW, and Brouwer KLR (2014) Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. *Drug Metab Dispos* **42**:665–674.
- Kojima H, Nies AT, König J, Hagmann W, Spring H, Uemura M, Fukui H, and Keppler D (2003) Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. *J Hepatol* **39**:693–702.
- König J, Rost D, Cui Y, and Keppler D (1999) Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. *Hepatology* **29**:1156–1163.
- Kumar V, Salphati L, Hop CECA, Xiao G, Lai Y, Mathias A, Chu X, Humphreys WG, Liao M, Heyward S, et al. (2019) A comparison of total and plasma membrane abundance of transporters in suspended, plated, sandwich-cultured human hepatocytes versus human liver tissue using quantitative targeted proteomics and cell surface biotinylation. *Drug Metab Dispos* **47**:350–357.
- Lee JK, Paine MF, and Brouwer KLR (2010) Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes. *J Pharmacol Exp Ther* **334**:410–418.
- Liao M, Zhu Q, Zhu A, Gemski C, Ma B, Guan E, Li AP, Xiao G, and Xia CQ (2019) Comparison of uptake transporter functions in hepatocytes in different species to determine the optimal model for evaluating drug transporter activities in humans. *Xenobiotica* **49**:852–862.
- Liu X, LeCluyse EL, Brouwer KR, Lightfoot RM, Lee JI, and Brouwer KLR (1999) Use of Ca²⁺ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. *J Pharmacol Exp Ther* **289**:1592–1599.
- Malinen MM, Ali I, Bezençon J, Beaudoin JJ, and Brouwer KLR (2018) Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury. *Am J Physiol Gastrointest Liver Physiol* **314**:G597–G609.
- Miszczuk GS, Barosso IR, Larocca MC, Marrone J, Marinelli RA, Boaglio AC, Sánchez Pozzi EJ, Roma MG, and Crocenzi FA (2018) Mechanisms of canalicular transporter endocytosis in the cholestatic rat liver. *Biochim Biophys Acta Mol Basis Dis* **1864** (4 Pt A):1072–1085.
- Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT II, Afshari CA, and Hamadeh HK (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. *Toxicol Sci* **136**:216–241.
- Morikawa A, Goto Y, Suzuki H, Hirohashi T, and Sugiyama Y (2000) Biliary excretion of 17beta-estradiol 17beta-D-glucuronide is predominantly mediated by cMOAT/MRP2. *Pharm Res* **17**:546–552.
- Mottino AD, Cao J, Veggi LM, Crocenzi F, Roma MG, and Vore M (2002) Altered localization and activity of canalicular Mrp2 in estradiol-17beta-D-glucuronide-induced cholestasis. *Hepatology* **35**:1409–1419.
- Musey PI, Wright K, Preedy JRK, and Collins DC (1997) Formation and metabolism of steroid conjugates: effect of conjugation on excretion and tissue distribution, in *Steroid Biochemistry Volume II* (Hobkirk R ed) pp 81–132, CRC Press, Boca Raton, FL.
- Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, and Artursson P (2008) Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). *J Med Chem* **51**:3275–3287.
- Pfeifer ND, Yang K, and Brouwer KLR (2013) Hepatic basolateral efflux contributes significantly to rosvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. *J Pharmacol Exp Ther* **347**:727–736.
- Slikker W Jr, Vore M, Bailey JR, Meyers M, and Montgomery C (1983) Hepatotoxic effects of estradiol-17 beta-D-glucuronide in the rat and monkey. *J Pharmacol Exp Ther* **225**:138–143.
- Sohlenius-Stembek AK (2006) Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. *Toxicol In Vitro* **20**:1582–1586.
- Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, and Meier PJ (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. *Gastroenterology* **118**:422–430.
- Swift B, Pfeifer ND, and Brouwer KLR (2010) Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. *Drug Metab Rev* **42**:446–471.
- Takikawa H, Sano N, Narita T, Uchida Y, Yamanaka M, Horie T, Mikami T, and Tagaya O (1991) Biliary excretion of bile acid conjugates in a hyperbilirubinemic mutant Sprague-Dawley rat. *Hepatology* **14**:352–360.
- Thakkar N, Slizgi JR, and Brouwer KLR (2017) Effect of liver disease on hepatic transporter expression and function. *J Pharm Sci* **106**:2282–2294.
- Vallejo M, Briz O, Serrano MA, Monte MJ, and Marin JJ (2006) Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. *J Hepatol* **44**:1150–1157.
- Vildhede A, Wiśniewski JR, Norén A, Karlgrén M, and Artursson P (2015) Comparative proteomic analysis of human liver tissue and isolated hepatocytes with a focus on proteins determining drug exposure. *J Proteome Res* **14**:3305–3314.
- Walker IA, Nelson-Piercy C, and Williamson C (2002) Role of bile acid measurement in pregnancy. *Ann Clin Biochem* **39**:105–113.
- Wang L, Prasad B, Salphati L, Chu X, Gupta A, Hop CE, Evers R, and Unadkat JD (2015) Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics. *Drug Metab Dispos* **43**:367–374.
- Yang K, Pfeifer ND, Köck K, and Brouwer KLR (2015) Species differences in hepatobiliary disposition of taurocholic acid in human and rat sandwich-cultured hepatocytes: implications for drug-induced liver injury. *J Pharmacol Exp Ther* **353**:415–423.
- Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, and Brouwer KLR (2006) Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. *Eur J Pharm Sci* **27**:447–486.
- Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, and Brouwer KLR (2009) Relationship between drug/metabolite exposure and impairment of excretory transport function. *Drug Metab Dispos* **37**:386–390.
- Zeng H, Liu G, Rea PA, and Kruh GD (2000) Transport of amphipathic anions by human multidrug resistance protein 3. *Cancer Res* **60**:4779–4784.
- Zollner G, Fickert P, Silbert D, Fuchsichler A, Marschall HU, Zatloukal K, Denk H, and Trauner M (2003) Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. *J Hepatol* **38**:717–727.
- Zollner G, Fickert P, Zenz R, Fuchsichler A, Stumptner C, Kenner L, Ferenci P, Stauber RE, Krejs GJ, Denk H, et al. (2001) Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. *Hepatology* **33**:633–646.
- Zollner G, Wagner M, Fickert P, Silbert D, Gumhold J, Zatloukal K, Denk H, and Trauner M (2007) Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. *Liver Int* **27**:920–929.

Address correspondence to: Kim L.R. Brouwer, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB #7569, 3205 Kerr Hall, Chapel Hill, NC 27599-7569. E-mail: kbrouwer@unc.edu